Merck & Co., Inc. (MRK) — SEC Filings

Latest SEC filings for Merck & Co., Inc. (MRK), explained in plain English.

Sentiment Overview: 1 bullish, 31 neutral

Recent Filings (32)

• 8-K Filing — 8-K · 2025-12-04T00:00:00.000Z [neutral]
• 13F-HR Filing — 13F-HR · 2025-11-12T00:00:00.000Z [neutral]
• 10-Q Filing — 10-Q · 2025-11-05T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-10-30T00:00:00.000Z [neutral]
• Merck & Co. Files 8-K on Financial Instruments — 8-K · 2025-09-09T00:00:00.000Z [neutral] Risk: low
  On September 9, 2025, Merck & Co., Inc. filed an 8-K report detailing various financial instruments, including common stock and several series of notes with var
• 13F-HR Filing — 13F-HR · 2025-08-13T00:00:00.000Z [neutral]
• Merck & Co. Files 2Q25 10-Q Financial Report — 10-Q · 2025-08-05T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its 10-Q for the period ending June 30, 2025. The filing provides financial updates for the second quarter of 2025. Key financial detail
• Merck & Co. Files 8-K on Financials and Exit Costs — 8-K · 2025-07-29T00:00:00.000Z [neutral] Risk: medium
  Merck & Co., Inc. filed an 8-K on July 29, 2025, reporting results of operations and financial condition as of July 25, 2025. The filing also details costs asso
• Merck & Co. Files 8-K on Security Holder Vote Matters — 8-K · 2025-05-29T00:00:00.000Z [neutral] Risk: low
  On May 27, 2025, Merck & Co., Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not specify the na
• 13F-HR Filing — 13F-HR · 2025-05-14T00:00:00.000Z [neutral]
• Merck & Co. Files Q1 2025 10-Q — 10-Q · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position. Key financial data p
• Merck & Co. Files 8-K on Financials — 8-K · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an 8-K on April 24, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and e
• Merck & Co. DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its DEF 14A on April 9, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31,
• Merck & Co. Files 2024 Annual Report — 10-K · 2025-02-25T00:00:00.000Z [neutral] Risk: medium
  Merck & Co., Inc. filed its 10-K for the fiscal year ended December 31, 2024, reporting on its operations in the pharmaceutical preparations industry. The compa
• 13F-HR Filing — 13F-HR · 2025-02-14T00:00:00.000Z [neutral]
• Merck & Co. Files 8-K on Financials — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an 8-K on February 4, 2025, to report on its results of operations and financial condition. The filing includes financial statements and
• Merck & Co. Files 8-K: Director Changes, Compensation, Bylaws — 8-K · 2024-11-22T00:00:00.000Z [neutral] Risk: low
  On November 19, 2024, Merck & Co., Inc. filed an 8-K report detailing several key events. The company announced the election of new directors and changes in off
• Merck & Co. Files 3Q24 10-Q Report — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position for the third qua
• SC 13G/A Filing — SC 13G/A · 2024-11-06T00:00:00.000Z [neutral]
• Merck & Co. Files 8-K on Financials — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an 8-K on October 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• Merck & Co. Files 10-Q for Q2 2024 — 10-Q · 2024-08-05T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and position. Key financial data po
• Merck & Co. Files 8-K on Financials and Debt — 8-K · 2024-07-30T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an 8-K on July 30, 2024, to report on its results of operations and financial condition. The filing includes financial statements and ex
• Merck & Co. Files 8-K on Shareholder Votes and Notes — 8-K · 2024-05-30T00:00:00.000Z [neutral] Risk: low
  On May 28, 2024, Merck & Co., Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and other events. The filing includes f
• Merck & Co. Files Q1 2024 10-Q Report — 10-Q · 2024-05-03T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed its 10-Q for the period ending March 31, 2024. The company, headquartered in Kenilworth, NJ, operates in the pharmaceutical preparations
• Merck & Co. Files 8-K on Financial Condition — 8-K · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an 8-K on April 25, 2024, reporting on its results of operations and financial condition. The filing includes details about various debt
• Merck Files 10-K/A Amendment for FY 2023 — 10-K/A · 2024-04-11T00:00:00.000Z [neutral] Risk: low
  Merck & Co., Inc. filed an amendment (10-K/A) on April 11, 2024, for its fiscal year ending December 31, 2023. This filing provides updated information for the
• Merck Files 2023 10-K, Details Pharmaceutical Operations — 10-K · 2024-02-26T00:00:00.000Z [neutral] Risk: medium
  Merck & Co., Inc. filed its 10-K on February 26, 2024, for the fiscal year ended December 31, 2023. The filing details the company's financial performance and o
• Merck 8-K Signals Potential Leadership or Compensation Changes — 8-K · 2024-02-20T00:00:00.000Z [neutral] Risk: medium
  Merck & Co., Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to "Departure of Directors or Ce
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Merck Files 8-K for Corporate Communications, Rule 425 & 14a-12 — 8-K · 2024-02-01T00:00:00.000Z [neutral]
  Merck & Co., Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 29, 2024. This filing indicates that Merck is satisfying its fil
• BlackRock Amends Merck Stake: Passive Investment Continues — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership of Merck & Co., Inc. common stock as of December 31, 2023. This filing, A
• Merck Discloses Passive Stake in Evaxion Biotech — SC 13G · 2024-01-23T00:00:00.000Z [bullish]
  Merck & Co., Inc. (MRK) has filed an SC 13G, disclosing its ownership of Evaxion Biotech A/S (EVAX) Ordinary Shares as of December 21, 2023. This filing indicat